This website uses cookies
Read our Privacy policy and Terms of use for more information.
All Posts
Regulatory
+2
/
Jul 27, 2026
Plus: an FDA warning letter over informed consent, and Nona's antibody platform heads to Vienna
Jul 19, 2026
Plus: the UK and Switzerland lock in pharma IP protections, Insilico's $2.5B pact with Bora, and AI discovery's shift to general design engines
Jul 12, 2026
Plus: NICE turns down Lumykras, Boehringer's new eye-health research team, and whether longevity biotech's billions are backed by evidence
Jul 6, 2026
Plus: Royalty Pharma opens in Hong Kong, Sarepta's push for full DMD approval, and why emerging-market R&D is no longer just generics
Jun 29, 2026
Plus: NewLimit's $435M raise for epigenetic reprogramming, the FDA's Operation Trailblazer, and a non-viral route to in vivo CAR-T
Jun 22, 2026
Plus: photosynthetic nanoparticles for inflamed eyes, Bayer scales histopathology AI on AMD chips, and Bulgaria reopens its medicines market
Jun 15, 2026
Plus: pramipexole's signal in anhedonic depression, Kardigan's $373M IPO filing, and Chiesi completes its $1.9B KalVista buy
Jun 8, 2026
Plus: the UK's £860M biomedical research call, Lilly's $1.9B RNA exon-editing pact with Ascidian, and Chinese biotechs take centre stage at ASCO
Jun 1, 2026
Plus: three FDA leadership exits in a single week, Biogen closes its $5.6B Apellis deal, and China's biotech rise unsettles its US rivals
